Matthew R. Cooperberg, MD, MPH, presented “Pros and Cons of the ReIMAGINE Trial” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.

This content is available free to the GRU Community. Login or create an account to view it.


Create an Account

How to cite: Cooperberg, Matthew R. “Pros and Cons of the ReIMAGINE Trial.” February 2024. Accessed Jun 2024.

Pros and Cons of the ReIMAGINE Trial – Summary

Matthew R. Cooperberg, MD, MPH, discusses the strengths and weaknesses of the Risk and Screening arms of the ongoing ReIMAGINE trial. He begins by describing the two arms of the study, ReIMAGINE Screening and ReIMAGINE Risk, and then focuses on the Screening arm, digging into the participant data.

Dr. Cooperberg addresses the sequence of screening tests in the ReIMAGINE trial, and reasserts the value of PSA as an initial screening marker, using supporting evidence from the ongoing STHLM3-MRI trial. He then briefly touches on ReIMAGINE Risk, noting that it will be useful as a biorepository in the future.

While ReIMAGINE Screening shows PSA with magnetic resonance imaging (MRI) is better than PSA alone, Dr. Cooperberg reiterates that, as an initial screening marker, PSA <1 (or 1.5) is tough to beat. Dr. Cooperberg explains that MRI is useful for helping to guide biopsy and is acceptable as a second screening tool. However, other markers are more effective and less expensive in the United States.


About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.